Is KLRS or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Tvardi Therapeutics N/A -64.17% -43.90%

Is ONCY or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -321.54% Tvardi Therapeutics N/A -64.17% -43.90%

Is ENGN or TVRD more profitable?

enGene's return on equity of -55.83% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Tvardi Therapeutics N/A -64.17% -43.90%

Do analysts prefer CYPH or TVRD?

Tvardi Therapeutics has a consensus price target of $53.60, indicating a potential upside of 1,640.26%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43

Is CYPH or TVRD more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Tvardi Therapeutics N/A -64.17% -43.90%

Does the media favor CYPH or TVRD?

In the previous week, Cypherpunk Technologies' average media sentiment score of 1.87 equaled Tvardi Therapeutics'average media sentiment score. Company Overall Sentiment Cypherpunk Technologies Very Positive Tvardi Therapeutics Very Positive

Do analysts recommend AIFC or TVRD?

Tvardi Therapeutics has a consensus price target of $53.60, suggesting a potential upside of 1,640.26%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43

Which has preferable earnings and valuation, AIFC or TVRD?

Tvardi Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 4.04 -$344.51M N/A N/A Tvardi Therapeutics $7.14M 4.05 -$18.21M -$3.10 N/A

Does the media favor AIFC or TVRD?

In the previous week, ALT5 Sigma's average media sentiment score of 1.87 equaled Tvardi Therapeutics'average media sentiment score. Company Overall Sentiment ALT5 Sigma Very Positive Tvardi Therapeutics Very Positive

Tvardi Therapeutics (TVRD) Competitors

$3.08 +0.13 (+4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$3.10 +0.02 (+0.49%)

As of 04:10 PM Eastern

Compare

TVRD vs. KLRS, ONCY, ENGN, CYPH, and AIFC

Should you buy Tvardi Therapeutics stock or one of its competitors? MarketBeat compares Tvardi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tvardi Therapeutics include Kalaris Therapeutics (KLRS), Oncolytics Biotech (ONCY), enGene (ENGN), Cypherpunk Technologies (CYPH), and ALT5 Sigma (AIFC). These companies are all part of the "pharmaceutical products" industry.

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Kalaris Therapeutics currently has a consensus price target of $15.60, suggesting a potential upside of 234.76%. Tvardi Therapeutics has a consensus price target of $53.60, suggesting a potential upside of 1,640.26%. Given Tvardi Therapeutics' higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Tvardi Therapeutics	$7.14M	4.05	-$18.21M	-$3.10	N/A

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 1 mentions for Kalaris Therapeutics and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.93 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Positive
Tvardi Therapeutics	Very Positive

Summary

Kalaris Therapeutics and Tvardi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Oncolytics Biotech presently has a consensus target price of $8.50, suggesting a potential upside of 880.39%. Tvardi Therapeutics has a consensus target price of $53.60, suggesting a potential upside of 1,640.26%. Given Tvardi Therapeutics' higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Tvardi Therapeutics' return on equity of -64.17% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tvardi Therapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Tvardi Therapeutics	$7.14M	4.05	-$18.21M	-$3.10	N/A

In the previous week, Oncolytics Biotech had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.87 beat Oncolytics Biotech's score of -0.54 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Negative
Tvardi Therapeutics	Very Positive

Summary

Tvardi Therapeutics beats Oncolytics Biotech on 9 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

In the previous week, enGene had 9 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 9 mentions for enGene and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.87 beat enGene's score of 0.27 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Tvardi Therapeutics	Very Positive

Tvardi Therapeutics has higher revenue and earnings than enGene. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Tvardi Therapeutics	$7.14M	4.05	-$18.21M	-$3.10	N/A

enGene currently has a consensus price target of $12.68, indicating a potential upside of 637.32%. Tvardi Therapeutics has a consensus price target of $53.60, indicating a potential upside of 1,640.26%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

64.2% of enGene shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

enGene has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

enGene's return on equity of -55.83% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Summary

Tvardi Therapeutics beats enGene on 8 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Cypherpunk Technologies has higher earnings, but lower revenue than Tvardi Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Tvardi Therapeutics	$7.14M	4.05	-$18.21M	-$3.10	N/A

Cypherpunk Technologies' return on equity of -48.33% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Tvardi Therapeutics has a consensus price target of $53.60, indicating a potential upside of 1,640.26%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Cypherpunk Technologies' average media sentiment score of 1.87 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Tvardi Therapeutics	Very Positive

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Tvardi Therapeutics beats Cypherpunk Technologies on 9 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Tvardi Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Tvardi Therapeutics' return on equity of -64.17% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

ALT5 Sigma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

In the previous week, ALT5 Sigma's average media sentiment score of 1.87 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
ALT5 Sigma	Very Positive
Tvardi Therapeutics	Very Positive

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tvardi Therapeutics has a consensus price target of $53.60, suggesting a potential upside of 1,640.26%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Tvardi Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	4.04	-$344.51M	N/A	N/A
Tvardi Therapeutics	$7.14M	4.05	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats ALT5 Sigma on 11 of the 13 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.67M	$3.28B	$6.30B	$12.44B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	-0.99	10.28	20.31	22.64
Price / Sales	4.05	317.72	518.49	115.68
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	1.38	6.77	9.98	6.72
Net Income	-$18.21M	$24.09M	$3.56B	$337.03M
7 Day Performance	-11.75%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-87.35%	48.90%	28.76%	33.98%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	2.1447 of 5 stars	$3.08 +4.4%	$53.60 +1,640.3%	-88.9%	$27.67M	$7.14M	N/A	80	Positive News
KLRS Kalaris Therapeutics	4.1782 of 5 stars	$5.27 +1.7%	$15.60 +196.0%	+53.2%	$125.39M	N/A	N/A	110
ONCY Oncolytics Biotech	3.6361 of 5 stars	$1.04 +11.2%	$8.50 +717.3%	+153.6%	$124.13M	N/A	N/A	30	High Trading Volume
ENGN enGene	4.1396 of 5 stars	$1.85 +3.9%	$12.68 +585.5%	-60.2%	$123.92M	N/A	N/A	31	Upcoming Earnings
CYPH Cypherpunk Technologies	1.0607 of 5 stars	$1.13 +0.9%	N/A	+218.5%	$120.31M	N/A	N/A	40	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. KLRS, ONCY, ENGN, CYPH, and AIFC

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Summary

How does Tvardi Therapeutics compare to Oncolytics Biotech?

Summary

How does Tvardi Therapeutics compare to enGene?

Summary

How does Tvardi Therapeutics compare to Cypherpunk Technologies?

Summary

How does Tvardi Therapeutics compare to ALT5 Sigma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. KLRS, ONCY, ENGN, CYPH, and AIFC

How does Tvardi Therapeutics compare to Kalaris Therapeutics?

Do analysts recommend KLRS or TVRD?

Which has more volatility and risk, KLRS or TVRD?

Is KLRS or TVRD more profitable?

Which has better earnings & valuation, KLRS or TVRD?

Do insiders & institutionals hold more shares of KLRS or TVRD?

Does the media prefer KLRS or TVRD?

Summary

How does Tvardi Therapeutics compare to Oncolytics Biotech?

Which has more volatility & risk, ONCY or TVRD?

Do analysts rate ONCY or TVRD?

Is ONCY or TVRD more profitable?

Do insiders & institutionals hold more shares of ONCY or TVRD?

Which has stronger valuation & earnings, ONCY or TVRD?

Does the media prefer ONCY or TVRD?

Summary

How does Tvardi Therapeutics compare to enGene?

Does the media prefer ENGN or TVRD?

Which has better earnings & valuation, ENGN or TVRD?

Do analysts prefer ENGN or TVRD?

Do institutionals and insiders believe in ENGN or TVRD?

Which has more volatility and risk, ENGN or TVRD?

Is ENGN or TVRD more profitable?

Summary

How does Tvardi Therapeutics compare to Cypherpunk Technologies?

Which has stronger earnings and valuation, CYPH or TVRD?

Is CYPH or TVRD more profitable?

Which has more risk and volatility, CYPH or TVRD?

Do analysts prefer CYPH or TVRD?

Does the media favor CYPH or TVRD?

Do insiders & institutionals believe in CYPH or TVRD?

Summary

How does Tvardi Therapeutics compare to ALT5 Sigma?

Is AIFC or TVRD more profitable?

Which has more volatility & risk, AIFC or TVRD?

Does the media favor AIFC or TVRD?

Do institutionals and insiders have more ownership in AIFC or TVRD?

Do analysts recommend AIFC or TVRD?

Which has preferable earnings and valuation, AIFC or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools